Graft-versus-host disease (GVHD) is a major complication after hemopoietic stem cell transplantation (HSCT), but its pathogenesis remains uncertain. Macrophage migratory inhibitory factor (MIF) is an important mediator in the allo-immune reaction during renal transplantation, yet its role in hemopoietic stem cell transplantation (HSCT) remains unexplored. This study investigated the potential role of MIF in acute graft-versus-host disease (aGVHD) following allogeneic HSCT. Forty-six randomly selected patients undergoing autologous or allogeneic HSCT were studied. Immunohistochemistry and in situ hybridization were performed to examine tissue MIF mRNA and protein expression on skin and colonic biopsy specimens. The associated T cell and macrophage activation was also studied by immunohistochemical studies. A semi-quantitative method was used to assess MIF staining, as well as T cell and macrophage staining. Serial blood samples were analyzed by ELISA for serum MIF levels. Immunohistochemistry and in situ hybridization performed in 15 skin and 19 colonic biopsies from 17 patients who developed moderate to severe aGVHD showed a significant increase in MIF mRNA and protein expression compared with normal controls (seven skin and five colonic biopsies). MIF was localized within the epidermis and the vascular area of skin, but diffusely expressed in the entire thickness of colon. Macrophage and T lymphocyte infiltration was confined to areas of strong MIF expression. Serial analysis by ELISA showed that only patients who developed aGVHD (n = 19) exhibited an increase (two-to three-fold) in serum MIF during HSCT, but not in the allogeneic HSCT recipients without aGVHD (n = 7) or those who received autologous HSCT (n = 8). In 14 out of 19 patients, serum MIF peaked before the onset of aGVHD. Local and systemic up-regulation of MIF expression is associated
Acute graft-versus-host disease (aGVHD) is a major complication after hematopoietic stem cell transplantation (HSCT). Its pathogenesis is not known with certainty but activation of donor-derived cytotoxic and helper T cells with the release of cytokines may be involved. [1] [2] [3] [4] Macrophage migration inhibitory factor (MIF) was first identified as a product of activated T cells that suppressed the random migration of macrophages in guinea pig peritoneal exudates in vitro. 5, 6 MIF has been demonstrated in corticotropic pituitary cells, macrophages and monocytes, as well as T lymphocytes, indicating that these tissues may be the source of MIF in vivo. [7] [8] [9] [10] In particular, T cell activation has been shown to elicit MIF release, whereas neutralizing anti-MIF antibodies inhibit T cell proliferation and IL-2 production in vitro. 10, 11 Recent studies have shown that local MIF expression is up-regulated in the allo-immune reaction during renal transplantation and it co-localizes with macrophage and T cell infiltration. [12] [13] These observations suggest that MIF may also play an important role in the pathogenesis of aGVHD after allogeneic HSCT. The present study was conducted to investigate the potential pathogenetic role of MIF in aGVHD.
Patients and methods

Patients
Archived specimen samples from 46 randomly selected patients undergoing HSCT from 1995 to 2000 at Queen Mary Hospital, Hong Kong, were studied. Their clinical characteristics are shown in Table 1 . CML = chronic myelogenous leukemia; AML = acute myelogenous leukemia; ALL = acute lymphoblastic leukemia; NHL = non-Hodgkin's lymphoma; Bu-Cy = busulphan/cyclophosphamide; Cy-TBI = cyclophosphamide/total body irradiation; CBV = cyclophosphamide, BCNU, etoposide; CarboPEC = carboplatin, etoposide, cyclophosphamide; CR = complete remission.
Post-transplantation treatment
In allogeneic HSCT, prophylaxis against GVHD consisted of methotrexate (15 mg/m 2 on day 1, 10 mg/m 2 on day 3, 6 and 11) and cyclosporin A (3 mg/kg/day intravenously or 9 mg/kg/day orally on days 1-50, tailed off at 6 months). The severity of GVHD was graded according to criteria described by Glucksberg et al. 14 Patients who developed GVHD received additional immunosuppression according to the discretion of the attending physicians.
Antibodies and probes
The following monoclonal antibodies (mAbs) for immunohistochemical staining were used. III.D.9, a mouse anti-MIF mAb was raised against purified recombinant mouse MIF protein (which shares 90% sequence homology with human MIF protein). The specificity of the anti-MIF antibody has been verified by Western blotting of whole tissue and by the co-expression of MIF mRNA and protein in tissue sections using double in situ hybridization and immunohistochemistry staining.
12,15 KP1 (Dakopatts, Glostrup, Denmark), mouse anti-CD68 labeling most monocytes and macrophages; UCHL1 (Dakopatts), mouse anti-CD45RO recognizing mature activated T cells and a subset of resting T cells. Peroxidase or alkaline phosphatase-labeled polymers conjugated to goat anti-mouse IgG supplied in DAKO EnVision TM +System were used for detection (Dako, CA, USA).
Monoclonal anti-human MIF antibody from a murine hybridoma raised against purified recombinant human MIF was used as a capture antibody for ELISA in combination with a biotinylated MIF affinity purified polyclonal detection antibody (R&D Systems, USA).
A 520-bp fragment of human MIF cDNA cloned into pCRII (Stratagene, La Jolla, CA, USA) was used to prepare digoxigenin (DIG)-labeled anti-sense and sense cRNA probes for in situ hybridization following the manufacturer's protocol (Roche Diagnostics, Mannheim, Germany). The specificity of human MIF probe has been documented in other studies.
12,16
Immunohistochemistry
Single and double immunostaining using mAbs to T cells (UCHLI, anti-CD45RO), macrophages (KP1, CD68) and MIF (III.D.9) were performed on 4-m formalin-fixed paraffin sections using a newly developed microwave-based method. 12, 13, [15] [16] [17] In short, sections were dewaxed and then treated by 10 min of microwave heating in 0.01 m sodium citrate buffer, pH 6.0 at 2450 MHz and 800 W. This treatment greatly facilitates the retrieval of cytoplasmic antigens. Any endogenous peroxidase activity was quenched by incubating with the peroxidase block (Dako Envision TM +System) according to the manufacturer's instructions. Sections then were labeled with CD45RO or CD68 mAbs (1:100 dilution) for 1 h, washed with PBS, followed by incubation with the peroxidase labeled polymer conjugated goat anti-mouse IgG (Dako) for 30 min and finally developed with 3,3Ј-diaminobenzidine (DAB+) substrate-chromogen to produce a brown-colored precipitate at the antigen site. For double immunostaining, sections were subjected to another microwave treatment to denature bound IgG, thereby preventing antibody cross-reactivity. 17 Sections were then labeled with anti-MIF mAb overnight. After washing with PBS, sections were incubated with alkaline phosphatase-labeled polymer conjugated goat antimouse IgG (Dako) and then developed with Fast Blue BB salt (Ajax Chemicals, Melbourne, Australia) to give a bluecolored product. Sections were counterstained with PAS and then mounted for microscopic examination.
In situ hybridization
In situ hybridization was performed on 4-m paraffin sections of formalin-fixed tissues using a microwave-based technique described. 12, 13, 15, 16, 18 After dewaxing, sections were treated with a microwave heating for 10 min as described above, incubated with 0.2 m HCl for 15 min, followed by 1% Triton X-100 for 15 min and then digested with 10 g/ml proteinase K at 37°C for 20 min (Roche Diagnostics). Sections then were washed with 2 ϫ SSC, prehybridized, and then hybridized with 0.5 ng/l DIG-labeled sense or anti-sense cRNA probe overnight at 42°C in a hybridization buffer containing 50% deionized formam-ide, 4 ϫ SSC, 1 mg/ml salmon sperm DNA (Sigma) and 1 mg/ml yeast tRNA. Sections were washed finally in 0.1 ϫ SSC at 42°C. Hybridized probe was detected by alkaline phosphatase-conjugated sheep anti-DIG F(ab) fragments and color development with nitro blue tetrazolium/X-phosphate. Sections were counterstained with PAS and mounted in an aqueous medium. Controls employed a sense MIF cRNA probe labeled to the same specific activity as the anti-sense probe, or omitted the probe completely. No staining was seen in either normal or diseased kidney using the sense probe or with no probe at all.
Quantitation of tissue staining
A semi-quantitative method was used to assess MIF staining, as well as T cell and macrophage staining. MIF staining was graded in terms of the percentage of positively stained cells on a scale of 1 (Ͻ25%), 2 (25-50%), 3 (50-75%), and 4 (Ͼ75%). To quantify macrophage and T cell staining, the number of labeled T cells or macrophages was counted under high power fields (magnification, ϫ40) by means of a 1 mm 2 graticule fitted in the eyepiece of the microscope. All counting was performed on blinded slides and the labeled cells are expressed as cells/mm 2 . For each tissue, the same area was examined in serial sections labeled with different mAbs. Data are expressed in terms of the mean Ϯ s.e.m.
Assay for serum MIF by enzyme-linked immunosorbent assay (ELISA)
Serum MIF concentrations were determined using the anti-MIF mAb as the capture antibody and incubating overnight in an ELISA plate at room temperature. The plates were washed three times with tris-buffer saline (TBS) with Tween and blocked with 3% BSA in TBS at room temperature for 1 h. After washing, serum samples were added to plates and incubated overnight at 4°C. The plates were washed, followed by an addition of biotin-conjugated goat anti-human MIF antibody and then alkaline phosphatasestreptavidin, incubating at room temperature for 1 h each. Finally, pNPP substrate was added for color development. Absorbance was read at a wavelength of 450 nm with a reference wavelength of 495 nm.
Statistical analysis
Data are expressed as means Ϯ s.e.m. Comparison between HSCT patients with and without aGVHD and normal controls was made using Mann-Whitney test (SPSS, Chicago, IL, USA). P values less than 0.05 were considered statistically significant.
Results
MIF mRNA and protein expression in aGVHD
In situ hybridization and immunohistochemistry were performed to examine tissue MIF mRNA and protein expression. In normal controls, MIF was constitutively Bone Marrow Transplantation expressed in the skin and colon (n = 7 and 5, respectively), but only weakly (Figures 1a, e and 2a, f) . In contrast, there was a dramatic increase in MIF mRNA and protein expression in both skin and colonic biopsies from 17 patients with moderate to severe aGVHD (denoted aGVHD group) (Figures 1 and 2) . MIF mRNA and protein staining was localized within the epidermis and vascular area in skin (Figures 1b, c and 2 b-e), whereas diffuse expression was observed throughout the entire mucosal and submucosal layers of colon (Figures 1f, g and 2 g-i) . The numbers of skin biopsies from the aGVHD group (n = 15) with scores of 1, 2, 3 and 4 were 0, 1, 4 and 10, respectively, whereas those of colonic biopsies (n = 19) were 0, 4, 5 and 10, respectively. All skin and colon sections from control subjects had a score of 1 in MIF expression. Serial tissue biopsies were available in one HSCT patient who developed severe aGVHD (overall grade 4). The intensity of MIF staining was increased as aGVHD progressed in severity (Figures 1f, g and 2g, i) . Figure 2 shows the immunohistochemical staining for MIF and T cell/macrophage activation markers (UCHL1, KP1) in skin and colonic biopsies during aGVHD. Up-regulation of MIF mRNA and protein expression was associated with T cell and macrophage accumulation in these tissues and two-color immunohistochemical studies revealed that these cells co-expressed MIF.
Association of MIF upregulation with T cell and macrophage infiltration
Quantitative and temporal relationships between serum MIF and aGVHD
Weekly serum samples from HSCT patients were studied starting from a week before transplantation. Serum levels of MIF from allogeneic (allo) HSCT patients with clinically moderate to severe aGVHD (overall grade (у2) (n = 19) or without significant aGVHD (overall grade р1) (n = 7), autologous (auto) HSCT patients (n = 8) and normal controls (n = 5) were measured by ELISA. Figure 3 shows the serum MIF levels in allogeneic HSCT patients with and without aGVHD and in autologous HSCT patients prior to conditioning, 2 weeks before marrow engraftment and at the onset of aGVHD. For patients without aGVHD, the levels at the first week after marrow engraftment were compared as this corresponded to the median time of aGVHD onset in the aGVHD group. There was no significant difference in MIF levels in three groups of patients prior to conditioning and 2 weeks before engraftment. However, the aGVHD group shows a significant increase in serum MIF at the onset of aGVHD (mean: aGVHD + 1593 Ϯ 195.8 pg/ml; aGVHD Ϫ 624.8 Ϯ 64.02 P Ͻ 0.05; autologous 629.6 Ϯ 122.4, P Ͻ 0.05; normal controls 368.9 Ϯ 136.0, P Ͻ 0.01). Table 2 shows the temporal relationships between onset of aGVHD and peak serum MIF in 19 patients in the aGVHD group. Fourteen patients had peak serum MIF before the onset of aGVHD (range, 1 to 14 days). On the other hand, two and three patients had peak MIF on the day of and after the onset of aGVHD (range, 1 to 10 days).
There was no correlation between the serum MIF levels and diagnoses.
Discussion
The present study demonstrated that local and systemic MIF expression was markedly up-regulated in aGVHD We found that intrinsic skin and colon cells were the major sites of MIF production in aGVHD. In normal skins and colons, MIF was constitutively expressed, but only at a weak level. By contrast, markedly increased expression of MIF mRNA and protein was found within the areas of aGVHD in the epithelial layer and blood vessels in skin and in the entire mucosal and submucosal layers of colon. This suggests that the up-regulation of local MIF expression contributes to the recruitment of T cells and macrophages to the site of aGVHD. Indeed, the dramatic increase in local MIF expression in aGVHD was found to be associated with an infiltration of activated T cells and macrophages, which was similar to the data obtained in renal allograft rejection in both an experimental rat model and in human patients. 12, 13 By contrast, there was very little T cell or macrophage infiltration in areas with weak MIF expression. These results support the known function of MIF to inhibit the random migration of macrophages, facilitating their interaction with various cell types leading to a generalized activation response as in delayed type hypersensitivity reaction (DTH). 5, 6, 19, 20 T cells and macrophages within the areas of aGVHD are the second major source of MIF. Indeed, the majority of T cells and macrophages within the GVHD lesions exhibited strong MIF expression. While MIF was originally identified as an activated T cell-derived, DTH-associated cytokine more than 30 years ago, the functional importance of MIF in DTH was documented only recently by administration of a neutralizing anti-MIF antibody. 5, 6, 21 It has also been shown that anti-MIF antibody inhibits T cell proliferation
Bone Marrow Transplantation and IL-2 production in vivo, demonstrating that MIF is intimately involved in T cell activation pathways. 10 T lymphocytes and macrophage/monocytes have been considered to play a central role in the pathogenesis of aGVHD, via cytokine release and induction of cytotoxic T lymphocyte and NK cell responses. 1, 4 Thus, the over-expression of local MIF may be involved in the development of aGVHD by stimulating the recruitment and activation of T cells and macrophages within the target tissues, leading to tissue destruction through the DTH mechanism.
In order to investigate the possible role of MIF in the pathogenesis of aGVHD, systemic levels of MIF mRNA in peripheral blood mononuclear cells and circulating MIF protein in serum were examined. Both MIF mRNA and protein levels in aGVHD patients were significantly higher than in non-GVHD patients or healthy individuals. Serum MIF levels of aGVHD patients at the onset of clinical aGVHD were increased at least two-fold and four-fold, respectively, when compared with those of HSCT patients without aGVHD and normal healthy controls. This elevated serum MIF level in aGVHD patients was found in the majority of the cases to precede the onset of aGVHD and showed a peak level of >1000 pg/ml. This suggests that MIF may be an important effector molecule in initiating aGVHD.
A number of studies have supported the concept that MIF is an integral mediator of systemic host responses. 8, 11, 22 MIF is secreted by the pituitary into the circulation upon stimulation of the hypothalamic-pituitary-adrenal (HPA) axis in response to stress and inflammation. 8, 11 Peripheral (monocyte/macrophage) MIF is released by pro-inflammatory stimuli, such as LPS and pro-inflammatory cytokines (TNF-␣ and IFN-␥). 9 The ability of anti-MIF antibody to protect against the lethality of endotoxemia and to inhibit the induction of renal injury in rat crescentic glomerulonephritis further supports that MIF action is pro-inflammatory. 8, 9, [23] [24] [25] [26] [27] Taken together, our findings suggest that MIF also may be one of the important mediators involved in the pathogenesis of aGVHD.
The results of this study are of potential therapeutic implication. At present, the optimal therapeutic strategy of established aGVHD has not been defined. The observation that MIF is involved in the pathogenesis of aGVHD suggests that blockade of its action may be explored as a target for anti-GVHD strategy. In vitro studies have demonstrated that anti-MIF antibody suppresses T cell proliferation and IL-2 release. 10, 11 Functional studies using anti-MIF antibody in an experimental model of aGVHD may be helpful in defining its role in the treatment of aGVHD.
In conclusion, the present study has demonstrated that both local and systemic MIF expression is up-regulated in aGVHD and that a marked increase in systemic MIF production precedes the onset of clinical aGVHD. Whether inhibition of the MIF pathway can prevent the occurrence or alleviate the severity of aGVHD will have to be tested by further studies in vivo.
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